Advertisement

Intraperitoneal recombinant interferongamma in ovarian cancer patients with residual disease at second look laparotomy

  • E. Pujade-Lauraine
  • J. P. Guastalla
  • N. Colombo
  • E. Francois
  • P. Fumoleau
  • A. Monnier
  • M. A. Nooy
  • L. Mignot
  • R. Bugat
  • C. M. D. Oliveira
  • M. Mousseau
  • G. Netter
  • F. Maloisel
  • S. Larbaoui
  • P. Devillier
  • M. Brandely

Abstract

Despite the improved overall response rate of debulking surgery and combination chemotherapy in advanced epithelial ovarian cancer, 60–70% of the patients have persistent disease at second look laparotomy [1,2].

Keywords

Ovarian Cancer Ovarian Carcinoma Epithelial Ovarian Cancer Ovarian Cancer Patient Intraperitoneal Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Piver, M.S. (ed.) (1987) Ovarian Malignancies: Diagnostic and Therapeutic Advances Churchill Livingstone, London, pp. 109–128.Google Scholar
  2. 2.
    Louie, K.G., Ozols, R.F., Myers, C.E. et al (1986) Long term results of a cis-platin containing combination chemotherapy regimen (Chex-up) for the treatment of advanced ovarian carcinoma. J. Clin. Oncol. 41579–85.PubMedGoogle Scholar
  3. 3.
    Howell, W.B., Pleifle, C.E., Wung, W.E. et al (1983) Intraperitoneal cis-diaminedichloro- platinum with systemic thiosulfate protection. Cancer Res. 43,1426–31.PubMedGoogle Scholar
  4. 4.
    Ten Bokkel Huinink, W.W., Dubbelman, R., Franklin, A. et al (1985) Experimental and clinical results with intraperitoneal cisplatin. Semin. Oncol 12,43–6.PubMedGoogle Scholar
  5. 5.
    Markman, M., Cleary, S., Lucas, W. et al (1986) IP chemotherapy employing a regimen of cisplatin, cytarabine and bleomycin.Cancer Treat. Rep. 70755–60.PubMedGoogle Scholar
  6. 6.
    Piver, M.S., Lele, S.B., Marchetti, D.L. et al (1988) Surgically documented response to intraperitoneal cisplatin, cytarabine and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J. Clin. Oncol 6,1679–84.PubMedGoogle Scholar
  7. 7.
    Oldham, R.K. (1984) Biologicals and biological response modifiers: fourth modality of cancer treatment. Cancer Treat Rep 68, 221–3.PubMedGoogle Scholar
  8. 8.
    Allavena, P., Grandi, M., DTncalci, M. et al (1987) Human tumor cell lines with pleiotropic drug resistance are efficiently killed by inter- leukin 2 activated killer cells and by activated monocytes. Int. J. Cancer 40104–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Berek, J.S., Hacker, N.F., Lichtenstein, A. et al (1985) Intraperitoneal recombinant alpha- interferon for ‘salvage’ immunotherapy in stage III epithelial ovarian cancer. Cancer Res 45 4447–53.PubMedGoogle Scholar
  10. 10.
    Lembersby, B., Baldisseri, M., Kunscher, A. et al (1989) Phase I-II study of intraperitoneal (IP) low dose of interleukin-2 (IL-2) in refractory stage III ovarian cancer (OC). Proc. Am. Soc. Clin. Oncol 8,636.Google Scholar
  11. 11.
    Bonnem, E.M. and Oldham, R.K. (1987) Gamma-interferon: physiology and speculation on its role in medicine. J. Biol Response Modif. 6 275–83.Google Scholar
  12. 12.
    Saito, T., Berens, M.E. and Welander, C.E. (1984) Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay. Cancer Res 461142–7.Google Scholar
  13. 13.
    Balkwill, F., Ward, B., Moodie, E. and Fiers, W. (1987) Therapeutic potential of tumor factor-a and y-interferon in experimental human ovarian cancer. Cancer Res 474755–8.PubMedGoogle Scholar
  14. 14.
    Malik, S.T.A., Knowles, R.G., East, N. et al (1991) Antitumor activity of gamma-interferon in ascitic and solid models of human ovarian cancer. Cancer Res 51 6643–9.PubMedGoogle Scholar
  15. 15.
    Marth, C., Müller-Holzner, E., Greiter, E. et al (1990) Gamma interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res 50, 7037–41.PubMedGoogle Scholar
  16. 16.
    Wallich, R., Bulbuc, N., Hammerling, G.J. et al (1985)Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315 301–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Tanaka, K., Hayashi, H., Hamada, C. et al (1986) Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of recognition of tumor cells. Proc. Natl Acad. Sci. USA 83 8723–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Weber, J., Jay, G., Tanaka, K. et al. (1987) Immunotherapy of a murine tumor with interleukin-2 increased sensitivity after MHC class I gene transfection. J. Exp. Med. 166 1716–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Allavena, P., Peccatori, F., Maggioni, D. et al (1990) Intraperitoneal recombinant y-inter- feron in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res 50 7318–23.PubMedGoogle Scholar
  20. 20.
    Mannel, D.N. and Falk, W. (1983) Interferon- gamma is required in activation of macrophages for cytotoxicity.Cell. Immunol 79 396–402.PubMedCrossRefGoogle Scholar
  21. 21.
    Saito, T., Berens, M.E. and Welander, C.E. (1987) Characterisation of the indirect antitumor effects of y-interferon using ascites- associated macrophages in a human tumor clonogenic assay. Cancer Res 47 673–9.PubMedGoogle Scholar
  22. 22.
    Colombo, N., Peccatori, F., Paganin, C. et al (1992) Antitumor and immunomodulatory activity of intraperitoneal interferon-gamma in ovarian carcinoma patients with minimal residual tumor after the chemotherapy. Int J. Cancer 5142–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Welander, C.E., Homesley, H.D., Reich, S.D. et al (1988) A Phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma.Am. J. Clin. Oncol II 455–60.Google Scholar
  24. 24.
    D’Acquisto, R., Markman, M., Hakes, T. et al (1988) A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma, J. Clin. Oncol 6, 689–95.PubMedGoogle Scholar
  25. 25.
    Belardelli, F., Greser, I., Maury, C. and Maunoury, M.T. (1982) Antitumor effects of interferon in mice injected with interferonsensitive and interferon-resistant friend leukemia cells. Int. J Cancer 30 813–20.PubMedCrossRefGoogle Scholar
  26. 26.
    Markman, M., Reichmann, B., Hakes, T. et al (1993) Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer 71 1465–70.CrossRefGoogle Scholar
  27. 27.
    Berek, J.S., Hacker, N., Lichtenstein, A. et al (1985) Intraperitoneal immunotherapy of epithelial ovarian cancer with Corynebacterium parvum. Am. J. Obstet. Gynecol 1521003–9.PubMedGoogle Scholar
  28. 28.
    Markman, M., Hakes, T., Reichman, B. et al (1991) Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma, J. Clin. Oncol 9204–10.PubMedGoogle Scholar
  29. 29.
    Willemse, P., de Vries, E., Mulder, N. et al (1990) Intraperitoneal human recombinant interferon alpha 2b in minimal residual disease ovarian cancer. Eur. J.Cancer 26353–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Nardi, M., Cognetti, F., Pollera, C.F. et al (1990) Intraperitoneal recombinant alpha-2- interferon alternating with cisplatin as salvage therapy for minimal residual disease ovarian cancer, J Clin. Oncol 8,1036–41.PubMedGoogle Scholar
  31. 31.
    Berek, J.S., Welander, C., Schink, J. C. et al (1991) A Phase I-II trial of intraperitoneal cisplatin and α-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol 40 237–43.PubMedCrossRefGoogle Scholar
  32. 32.
    Markman, M., Cleary, S., Lucas, W.E. et al (1986) Intraperitoneal chemotherapy employing a regimen of cisplatin, cytarabine and bleomycin. Cancer Treat. Rep. 70 755–60.PubMedGoogle Scholar
  33. 33.
    Ovarian Cancer Meta-Analysis Project (1991) Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis, J.Clin. Oncol 9, 1668–74.Google Scholar
  34. 34.
    Markman, M., Reichman, B., Hakes, T. et al (1991) Responses to second-hne cisplatin- based intraperitoneal therapy in ovarian cancer: influence of prior response to intravenous cisplatin. J. Clin. Oncol 91801–5.PubMedGoogle Scholar
  35. 35.
    Piccart, M., Speyer, J.L., Markman, M. et al (1985) Intraperitoneal chemotherapy: technical experiences at five institutions. Semin. Oncol 8,1618–29.Google Scholar
  36. 36.
    Lotze, M.T., Custer, M.C. and Rosenberg, S.A. (1986)Intraperitoneal administration of inter- leukin-2 in patients with cancer.Arch. Surg. 1211373–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Rambaldi, A., Introna, M., Colotta, F. et al (1985) Intraperitoneal administration of interferon ß in ovarian cancer patients. Cancer 56 294–301.PubMedCrossRefGoogle Scholar
  38. 38.
    Elias, J. A., Jimenez, S.A. and Freundlich, B. (1987)Recombinant gamma, alpha, and beta interferons regulation of human lung fibroblast proliferation. Am. Rev. Respir. Dis. 135 62–5.PubMedGoogle Scholar
  39. 39.
    Kähäri, V.M., Heino, J., Vuorio, T. and Vuorio, E. (1988) Interferon-of and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture. Biochem. Biophys. Acta 968 45–50.PubMedCrossRefGoogle Scholar
  40. 40.
    Giri, S. N., Hyde, D.M. and Marafin, B.J. (1986) Ameliorating effect of murine gamma- interferon on bleomycin-induced lung collagen fibrosis in mice. Biochem. Med. Meth. Biol. 36,194–7.CrossRefGoogle Scholar
  41. 41.
    Granstein, R.D., Murphy, E.G., Margolis, R.G. et al. (1987) Gamma interferon inhibits collagen synthesis in vivo in the mouse J. Clin. Invest. 791254–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Björkholm, E., Petersson, F., Einhorn, N. et al (1982) Long term follow-up and prognostic factors in ovarian carcinoma: the Radiumhemmet series 1958–1973. Acta Radiol. Oncol. Radiat. Phys. Biol 21 413–19.Google Scholar
  43. 43.
    Lippman, S.M., Alberts, D.S. Slymen, D.J. et al (1988) Second look laparotomy in epithehal ovarian carcinoma. Cancer 61 2571–7.PubMedCrossRefGoogle Scholar
  44. 44.
    De Gramont, A., Drolet, Y., Varette, C. et al (1989) Survival after second look laparotomy in advanced epithelial cancer. Eur.J. Cancer Clin. Oncol 25 251–7.CrossRefGoogle Scholar
  45. 45.
    Chambers, S.K., Chambers, J.T., Kohorn, E.I. et al (1988) Evaluation of the role of second look surgery in ovarian cancer. Obstet. Gynecol 72 404–8.PubMedGoogle Scholar
  46. 46.
    Saito, T., Berens, M.E. and Welander, C.E. (1987) Interferon gamma and cytotoxic agents studied in combination using a soft agarose human tumor clonogenic assay. Cancer Chemother. Pharmacol 19233–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Mutch, D.G., Massard, S.L., Kao, M.S. and Collins, J.L. (1990) Proliferative and antiproliferative effects of interferon-7 and tumor necrosis factor-a on cell lines derived from cervical and ovarian malignancies.Am.J. Obstet. Gynecol 1631920–4.PubMedGoogle Scholar
  48. 48.
    Maekawa, R., Kitagawa, T., Hojok, R. et al (1988) Differential efficacies of recombinant interferon y and recombinant human inter- leukin-2 against EL4-bearing mice. J Interferon Res. 8 241–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Silagi, S., Dutkowski, R. Schaeger, A. et al (1988) Eradication of mouse melanoma by combined treatment with recombinant human interleukin-2 and recombinant murine interferon gamma. Int. J. Cancer. 41 315–22.PubMedCrossRefGoogle Scholar

Copyright information

© Chapman & Hall 1995

Authors and Affiliations

  • E. Pujade-Lauraine
  • J. P. Guastalla
  • N. Colombo
  • E. Francois
  • P. Fumoleau
  • A. Monnier
  • M. A. Nooy
  • L. Mignot
  • R. Bugat
  • C. M. D. Oliveira
  • M. Mousseau
  • G. Netter
  • F. Maloisel
  • S. Larbaoui
  • P. Devillier
  • M. Brandely

There are no affiliations available

Personalised recommendations